Keenova Presents New TERLIVAZ® (terlipressin) Clinical Analysis at SHM Converge

Analysis examines real-world utilization patterns and outcomes in hospitalized U.S. adults with hepatorenal syndrome-acute kidney injury treated with terlipressin

Mar. 27, 2026 at 12:33pm

Got story updates? Submit your updates here. ›

Keenova Therapeutics announced that a new presentation on hepatorenal syndrome-acute kidney injury (HRS‑AKI) and TERLIVAZ ® (terlipressin) will be shared at the Society of Hospital Medicine (SHM) Converge conference. The analysis provides insights into how clinicians are using TERLIVAZ in practice and how Keenova can continue to support patients affected by HRS-AKI, a life-threatening condition marked by rapid kidney function decline.

Why it matters

Expanding the clinical evidence base for TERLIVAZ, the first and only FDA-approved therapy to improve kidney function in adults with HRS-AKI, is essential as this condition is associated with high morbidity and mortality. The analysis aims to deepen understanding of this challenging condition and how the treatment is being utilized in real-world settings.

The details

The presentation, titled "Real-World Utilization Patterns and Outcomes in Hospitalized U.S. Adults With Hepatorenal Syndrome-Acute Kidney Injury Treated with Terlipressin: A Retrospective Cohort Study", will be delivered by a team of authors including A. Sidney Barritt IV, MD; Kavish R. Patidar, DO; Robert J. Wong, MD, MS; and others. HRS-AKI is an acute medical emergency that requires hospitalization, and a recent U.S. study found the projected annual number of inpatients diagnosed with HRS has increased from 42,930 in 2018 to 63,381 in 2023.

  • The SHM Converge conference will take place from March 29 to April 1, 2026.
  • Keenova announced the new TERLIVAZ presentation on March 27, 2026.

The players

Keenova Therapeutics plc

A leading U.S.-focused branded therapeutics company that strives to help patients with rare or unaddressed conditions live happier and healthier lives.

TERLIVAZ

The first and only FDA-approved therapy indicated to improve kidney function in adults with hepatorenal syndrome-acute kidney injury (HRS-AKI).

A. Sidney Barritt IV, MD

One of the authors presenting the new TERLIVAZ analysis at the SHM Converge conference.

Kavish R. Patidar, DO

One of the authors presenting the new TERLIVAZ analysis at the SHM Converge conference.

Robert J. Wong, MD, MS

One of the authors presenting the new TERLIVAZ analysis at the SHM Converge conference.

Got photos? Submit your photos here. ›

What they’re saying

“We are pleased to share these findings with the medical community, as they help deepen our understanding of this challenging and rapidly progressive condition. Expanding the clinical evidence base is essential, and this analysis provides fresh insight into how clinicians are using TERLIVAZ in practice and how we can continue to support patients affected by HRS-AKI.”

— Dr. Marek Honczarenko, Executive Vice President and Chief Scientific Officer at Keenova

What’s next

The new TERLIVAZ analysis will be presented at the SHM Converge conference from March 29 to April 1, 2026, providing the medical community with additional insights into the real-world use and outcomes of the therapy for patients with HRS-AKI.

The takeaway

This new TERLIVAZ analysis aims to further expand the clinical evidence base for the only FDA-approved therapy to improve kidney function in adults with the life-threatening condition of hepatorenal syndrome-acute kidney injury, which is associated with high morbidity and mortality rates.